RHON-KLINIKUM AG (DE:RHK)
XETRA:RHK
Want to see DE:RHK full AI Analyst Report?
Top Page
RHON-KLINIKUM AG
(XETRA:RHK)
Select Model
Select Model
Rating:57Neutral
Price Target:
€12.50
▼(-3.10% Downside)
Action:Downgraded
Date:03/28/26
The score is anchored by a strong, low-leverage balance sheet, but is held back by weaker 2025 profitability and negative free cash flow. Technicals are also unfavorable with the stock trading below major moving averages and negative momentum, while valuation looks only moderate with a low dividend yield.
Positive Factors
Conservative balance sheet
The company’s low leverage and rising equity provide a durable financial cushion that supports operating flexibility and downturn resilience. With total debt reduced and sizable equity, RHÖN-KLINIKUM can absorb temporary cash-flow variability, invest selectively, and access capital without immediate solvency pressure.
Negative Factors
Sharp EBIT collapse in 2025
A near-total collapse in operating profit signals structural margin pressure or major one-off costs that materially reduce operating leverage. Persistently depressed EBIT undermines reinvestment, raises sensitivity to reimbursement changes, and could force cost restructuring or limit strategic initiatives over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
The company’s low leverage and rising equity provide a durable financial cushion that supports operating flexibility and downturn resilience. With total debt reduced and sizable equity, RHÖN-KLINIKUM can absorb temporary cash-flow variability, invest selectively, and access capital without immediate solvency pressure.
Read all positive factors
RHON-KLINIKUM AG (RHK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€843.42M
Dividend Yield0.77%
Average Volume (3M)955.00
Price to Earnings (P/E)16.3
Beta (1Y)-0.18
Revenue Growth6.06%
EPS Growth0.93%
CountryDE
Employees18,819
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.56
Shares Outstanding66,962,470
10 Day Avg. Volume528
30 Day Avg. Volume955
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)0.64
Price to Sales (P/S)0.44
P/FCF Ratio-24.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.76
Revenue Forecast (FY)€1.79B
RHON-KLINIKUM AG Business Overview & Revenue Model
Company Description
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, offers in-patient, semi-patient, and outpatient healthcare services in Germany. Its hospitals offer treatment services, including rehabilitation of cardiovascular patients, hand sur...
How the Company Makes Money
RHÖN-KLINIKUM AG makes money primarily by delivering medical treatment services through its hospitals and billing payers for patient care. Revenue is generated from inpatient hospital stays (e.g., admissions, procedures, surgeries, intensive care,...
RHON-KLINIKUM AG Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.94B | 1.60B | 1.73B | 1.45B | 1.40B |
| Gross Profit | 499.52M | 167.75M | 171.82M | 202.88M | 999.52M | 182.63M |
| EBITDA | 115.77M | 69.40M | 122.23M | 116.58M | 106.15M | 100.21M |
| Net Income | 37.68M | 34.47M | 43.35M | 38.71M | 25.14M | 28.30M |
Balance Sheet | ||||||
| Total Assets | 1.87B | 1.82B | 1.86B | 1.77B | 1.70B | 1.67B |
| Cash, Cash Equivalents and Short-Term Investments | 346.19M | 329.85M | 426.66M | 342.84M | 296.33M | 292.12M |
| Total Debt | 146.87M | 122.17M | 149.60M | 149.84M | 158.20M | 159.76M |
| Total Liabilities | 535.79M | 467.50M | 530.51M | 490.30M | 453.51M | 440.82M |
| Stockholders Equity | 1.30B | 1.32B | 1.30B | 1.25B | 1.22B | 1.20B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -34.60M | 57.20M | 46.20M | -16.90M | 19.70M |
| Operating Cash Flow | 0.00 | 64.50M | 127.60M | 109.00M | 60.30M | 97.50M |
| Investing Cash Flow | 0.00 | -132.10M | -50.40M | 40.90M | -105.20M | -58.30M |
| Financing Cash Flow | 0.00 | -42.00M | -3.30M | -21.20M | -4.10M | -3.90M |
RHON-KLINIKUM AG Technical Analysis
Negative
12.90
Price Trends
12.77
Negative
12.77
Negative
12.31
Negative
Market Momentum
-0.13
Positive
37.41
Neutral
36.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:RHK, the sentiment is Negative. The current price of 12.9 is above the 20-day moving average (MA) of 12.43, above the 50-day MA of 12.77, and above the 200-day MA of 12.31, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 37.41 is Neutral, neither overbought nor oversold. The STOCH value of 36.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:RHK.
RHON-KLINIKUM AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €362.35M | 6.07 | 15.83% | 2.80% | 6.52% | 7.17% | |
74 Outperform | €151.50M | 18.52 | 22.77% | ― | 33.49% | 81.79% | |
65 Neutral | €169.10M | 116.46 | 10.71% | 1.12% | 5.13% | 11.89% | |
57 Neutral | €843.42M | 16.32 | 3.04% | 0.77% | 6.06% | 0.93% | |
57 Neutral | €10.81B | 22.49 | 7.26% | 3.54% | -0.69% | 55.62% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
41 Neutral | €20.76M | -1.54 | 23.56% | ― | 3.51% | -5.66% |
* General Sector Average
DE:RHK
RHON-KLINIKUM AG
12.70
-0.39
-2.99%
DE:FME
Fresenius Medical Care AG & Co. KGaA
38.12
-12.12
-24.13%
DE:MED
MEDICLIN
3.52
0.66
23.08%
DE:MAK
MATERNUS-Kliniken AG
1.01
-0.54
-34.84%
DE:LIK
Limes Schlosskliniken AG
505.00
207.00
69.46%
DE:M12
M1 Kliniken AG
18.76
4.64
32.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.